Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma
Abstract
BACKGROUND: In marginal zone lymphoma (MZL), clinical and follow‐up data on large cohorts of patients are difficult to obtain. The objective of this single‐center, retrospective analysis of a large cohort of 144 patients with MZL was to elucidate the role of prognostic markers, treatments, and outcomes in this disease.METHODS: In total, 144 patients were identified who were diagnosed with MZL at the authors' institution between 2003 and 2010. Data on clinical parameters, treatments, response, and survival were analyzed. In addition, the validity of the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) prognostic scores were tested in patients with MZL.RESULTS: Among 144 patients with MZL, 96 patients (67%) had extralymph node (extranodal) MZL, 32 patients (22%) had lymph node (nodal) MZL, and 16 patients (11%) had splenic MZL. The 5‐year progression‐free survival rate was 82% in the nodal MZL group, 88% in the extranodal MZL group, and 74% in the splenic MZL group and did not different between the 3 groups (P = .60). The 5‐year overall survival rate was excellent in all 3 MZL groups (nodal MZL, 89%; extranodal MZL, 92%; splenic MZL, 82%; P = .46). In our cohort, the FLIPI score was a significant prognostic marker: The 5‐year progression‐free survival rate for patients who had FLIPI scores of 0 to 2 (low or intermediate risk) was excellent at 92%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (poor risk; P = .003). Similarly, the 5‐year overall survival rate for patients who had FLIPI scores of 0 to 2 was 95%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (P = .0009).CONCLUSIONS: The FLIPI score had strong prognostic value in patients with MZL. Patients who have low‐risk or intermediate‐risk FLIPI scores have an excellent prognosis, whereas patients with poor‐risk FLIPI scores are candidates for novel treatment approaches. Cancer 2013. © 2012 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesLaboratory Investigation, 2012
- Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupBlood, 2010
- Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteriaLeukemia, 2007
- MALT lymphoma: from morphology to moleculesNature Reviews Cancer, 2004
- Most cases of primary salivary mucosa‐associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infectionBritish Journal of Haematology, 2004
- Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal LymphomasJNCI: Journal of the National Cancer Institute, 2004
- Immunoproliferative Small Intestinal Disease Associated withCampylobacter jejuniNew England Journal of Medicine, 2004
- Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsBritish Journal of Haematology, 2003
- High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphomaBlood, 2002
- Helicobacter pylori-associated gastritis and primary B-cell gastric lymphomaThe Lancet, 1991